Who makes LAE102 intravenous administration?

LAE102 intravenous administration is developed by Laekna Limited.

What development phase is LAE102 intravenous administration in?

LAE102 intravenous administration is in Phase 1.

Last reviewed 2026-04-20 · How we verify

LAE102 intravenous administration

Laekna Limited · Phase 1 active Small molecule Quality 3/100

At a glance

Generic name	LAE102 intravenous administration
Also known as	LAE102 IV
Sponsor	Laekna Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate LAE102 in Healthy and Overweight/Obese Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LAE102 intravenous administration CI brief — competitive landscape report
LAE102 intravenous administration updates RSS · CI watch RSS
Laekna Limited portfolio CI